Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orathecin and Gemcitabine in Pancreatic Cancer
NCT00113256Phase 3Terminated
- Sponsor
- Astex Pharmaceuticals
- Start
- Feb 2005
- Primary completion
- Feb 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rubitecan in pancreatic cancer (PC), sponsored by Astex Pharmaceuticals. Started Feb 2005; status: terminated.
02
Drugs
rubitecan
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00113256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00113256.